Recro Pharma, Inc. (NASDAQ:REPH) major shareholder Healthcare Master Fun Broadfin sold 222,616 shares of the stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $9.58, for a total value of $2,132,661.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Healthcare Master Fun Broadfin also recently made the following trade(s):

  • On Tuesday, November 28th, Healthcare Master Fun Broadfin sold 47,549 shares of Recro Pharma stock. The shares were sold at an average price of $9.64, for a total value of $458,372.36.
  • On Tuesday, November 21st, Healthcare Master Fun Broadfin sold 102,440 shares of Recro Pharma stock. The shares were sold at an average price of $9.50, for a total value of $973,180.00.
  • On Friday, November 24th, Healthcare Master Fun Broadfin sold 172,208 shares of Recro Pharma stock. The stock was sold at an average price of $9.45, for a total value of $1,627,365.60.

Recro Pharma, Inc. (REPH) traded down $0.04 during trading hours on Thursday, hitting $9.64. The stock had a trading volume of 225,226 shares, compared to its average volume of 119,135. Recro Pharma, Inc. has a fifty-two week low of $5.81 and a fifty-two week high of $9.90. The company has a current ratio of 1.59, a quick ratio of 1.35 and a debt-to-equity ratio of 0.50.

Large investors have recently added to or reduced their stakes in the company. JT Stratford LLC bought a new position in shares of Recro Pharma during the 2nd quarter valued at about $704,000. Essex Investment Management Co. LLC lifted its holdings in shares of Recro Pharma by 40.3% during the 3rd quarter. Essex Investment Management Co. LLC now owns 93,199 shares of the specialty pharmaceutical company’s stock valued at $837,000 after purchasing an additional 26,785 shares in the last quarter. TIAA CREF Investment Management LLC bought a new position in shares of Recro Pharma during the 2nd quarter valued at about $249,000. Teachers Advisors LLC bought a new position in shares of Recro Pharma during the 2nd quarter valued at about $162,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Recro Pharma by 373.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 60,276 shares of the specialty pharmaceutical company’s stock valued at $424,000 after purchasing an additional 47,557 shares in the last quarter. Institutional investors and hedge funds own 61.55% of the company’s stock.

REPH has been the subject of a number of research reports. Zacks Investment Research lowered Recro Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Piper Jaffray Companies reiterated a “buy” rating and issued a $11.00 price target on shares of Recro Pharma in a report on Friday, October 27th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $11.65.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/11/30/recro-pharma-inc-reph-major-shareholder-sells-2132661-28-in-stock.html.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Insider Buying and Selling by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.